5F-PB-22: Difference between revisions

Line 6:

| ''[[5F-PB-22/Summary|Summary sheet: 5F-PB-22]]''

|}

'''5F-PB-22''' ('''1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester''')<ref>http://link.springer.com/article/10.1007/s00216-014-7668-0</ref><ref>https://www.caymanchem.com/msdss/13169m.pdf</ref> is a synthetic [[cannabinoid]] <ref>http://www.publish.csiro.au/nid/51</ref> and agonist of the [[Psychoactive class::cannabinoid]] receptors which produces predominantly [[sedation|sedating]] subjective effects somewhat similar to that of [[cannabis]]. There is very little information regarding the pharmacology of this compound within the scientific literature. Despite this, however, it has been sold as a grey area [[research chemical]] through online vendors.

'''5F-PB-22''' ('''1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester''')<ref>http://link.springer.com/article/10.1007/s00216-014-7668-0</ref><ref>https://www.caymanchem.com/msdss/13169m.pdf</ref> is a synthetic [[cannabinoid]]<ref>http://www.publish.csiro.au/nid/51</ref> and agonist of the [[Psychoactive class::cannabinoid]] receptors which produces predominantly [[sedation|sedating]] subjective effects somewhat similar to that of [[cannabis]]. There is very little information regarding the pharmacology of this compound within the scientific literature. Despite this, however, it has been sold as a grey area [[research chemical]] through online vendors.

Cannabinoids are commonly smoked or vaporized to achieve a quick [[onset]] of effects and rapid [[offset]]. 5F-PB-22 is [[oral]]ly active when dissolved in a lipid, which can increase the duration significantly. Like other [[cannabinoid]]s, it is insoluble in water but dissolves in [[ethanol]] and lipids.

Line 26:

*'''[[Effect::Dehydration]]'''- This is known colloquially as "cotton mouth" in popular American and United Kingdom culture.

*'''[[Effect::Vasodilation]]''' - Cannabinoids appear to decrease blood pressure by dilating the blood vessels and increasing blood flow throughout the body. The arteries in the eyeball expand from the decreased blood pressure and the heart rate increases to compensate for the reduction in pressure.

*'''[[Effect::Pain relief]]''' - Cannabinoids have been clinically demonstrated to provide pain relief via agonism of cannabinoid receptors CB1 and CB2, which extends to [[synthetic cannabinoid]] receptor agonists. <ref>http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4637.2009.00703.x/abstract</ref><ref>Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2011.03970.x/abstract</ref>

*'''[[Effect::Pain relief]]''' - Cannabinoids have been clinically demonstrated to provide pain relief via agonism of cannabinoid receptors CB1 and CB2, which extends to [[synthetic cannabinoid]] receptor agonists.<ref>http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4637.2009.00703.x/abstract</ref><ref>Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2011.03970.x/abstract</ref>

*'''[[Effect::Perception of increased weight]]''' ''or'' '''[[Perception of decreased weight|Perception of decreased weight]]'''

*'''[[Effect::Changes in gravity]]''' - 5F-PB-22, like other cannabinoids, is capable of causing vertigo with which the environment appears to be spinning or oscillating. At moderate doses, it can spontaneously induce the sensation of falling, which can be overwhelming and uncomfortable. The propensity of this is greatly reduced and eliminated in proportion to tolerance.

Line 78:

==Legal issues==

*'''United States:''' In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States. <ref>http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm</ref>

*'''United States:''' In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States.<ref>http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm</ref>

*'''Germany''': On December 13, 2014 5F-PB-22 was added to the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.<ref>Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften (28. BtMÄndV)| http://www.buzer.de/gesetz/11392/a189949.htm</ref>

*'''Latvia:''' 5F-PB-22 is a Schedule I drug.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Indola-3-karbonskābes esteri) | http://likumi.lv/doc.php?id=121086</ref>

@@ Line 6: / Line 6: @@
 | ''[[5F-PB-22/Summary|Summary sheet: 5F-PB-22]]''
 |}
-'''5F-PB-22''' ('''1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester''')<ref>http://link.springer.com/article/10.1007/s00216-014-7668-0</ref><ref>https://www.caymanchem.com/msdss/13169m.pdf</ref> is a synthetic [[cannabinoid]] <ref>http://www.publish.csiro.au/nid/51</ref> and agonist of the [[Psychoactive class::cannabinoid]] receptors which produces predominantly [[sedation|sedating]] subjective effects somewhat similar to that of [[cannabis]]. There is very little information regarding the pharmacology of this compound within the scientific literature. Despite this, however, it has been sold as a grey area [[research chemical]] through online vendors.
+'''5F-PB-22''' ('''1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester''')<ref>http://link.springer.com/article/10.1007/s00216-014-7668-0</ref><ref>https://www.caymanchem.com/msdss/13169m.pdf</ref> is a synthetic [[cannabinoid]]<ref>http://www.publish.csiro.au/nid/51</ref> and agonist of the [[Psychoactive class::cannabinoid]] receptors which produces predominantly [[sedation|sedating]] subjective effects somewhat similar to that of [[cannabis]]. There is very little information regarding the pharmacology of this compound within the scientific literature. Despite this, however, it has been sold as a grey area [[research chemical]] through online vendors.
 Cannabinoids are commonly smoked or vaporized to achieve a quick [[onset]] of effects and rapid [[offset]]. 5F-PB-22 is [[oral]]ly active when dissolved in a lipid, which can increase the duration significantly. Like other [[cannabinoid]]s, it is insoluble in water but dissolves in [[ethanol]] and lipids.
@@ Line 26: / Line 26: @@
 *'''[[Effect::Dehydration]]'''- This is known colloquially as "cotton mouth" in popular American and United Kingdom culture.
 *'''[[Effect::Vasodilation]]''' - Cannabinoids appear to decrease blood pressure by dilating the blood vessels and increasing blood flow throughout the body. The arteries in the eyeball expand from the decreased blood pressure and the heart rate increases to compensate for the reduction in pressure.
-*'''[[Effect::Pain relief]]''' - Cannabinoids have been clinically demonstrated to provide pain relief via agonism of cannabinoid receptors CB<sub>1</sub> and CB<sub>2</sub>, which extends to [[synthetic cannabinoid]] receptor agonists. <ref>http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4637.2009.00703.x/abstract</ref><ref>Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2011.03970.x/abstract</ref>
+*'''[[Effect::Pain relief]]''' - Cannabinoids have been clinically demonstrated to provide pain relief via agonism of cannabinoid receptors CB<sub>1</sub> and CB<sub>2</sub>, which extends to [[synthetic cannabinoid]] receptor agonists.<ref>http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4637.2009.00703.x/abstract</ref><ref>Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2011.03970.x/abstract</ref>
 *'''[[Effect::Perception of increased weight]]''' ''or'' '''[[Perception of decreased weight|Perception of decreased weight]]'''
 *'''[[Effect::Changes in gravity]]''' - 5F-PB-22, like other cannabinoids, is capable of causing vertigo with which the environment appears to be spinning or oscillating. At moderate doses, it can spontaneously induce the sensation of falling, which can be overwhelming and uncomfortable. The propensity of this is greatly reduced and eliminated in proportion to tolerance.
@@ Line 78: / Line 78: @@
 ==Legal issues==
-*'''United States:'''	In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States. <ref>http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm</ref>
+*'''United States:'''	In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States.<ref>http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm</ref>
 *'''Germany''': On December 13, 2014 5F-PB-22 was added to the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.<ref>Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften (28. BtMÄndV)| http://www.buzer.de/gesetz/11392/a189949.htm</ref>
 *'''Latvia:''' 5F-PB-22 is a Schedule I drug.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Indola-3-karbonskābes esteri) | http://likumi.lv/doc.php?id=121086</ref>